|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial显示文摘 | Yung-Jue Bang Eric Van Cutsem Andrea Feyereislova Hyun C Chung Lin Shen Akira Sawaki Florian Lordick Atsushi Ohtsu Yasushi Omuro Taroh Satoh Giuseppe Aprile Evgeny Kulikov Julie Hill Michaela Lehle Josef Rüschoff Yoon-Koo Kang | 2010 | The Lancet2010，，9742： | 20 |
| 2 | Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer:A critical update显示文摘Gastrointestinal toxicities(GIT), including oral mucositis,nausea and vomiting, and diarrhea, are common side effects of chemotherapy and targeted agents in patients with advanced colorectal cancer and pancreatic cancer. Being often underreported, it is still difficult to precisely establish their burden in terms of both patient's quality of life and cancer care costs. Moreover, with the use of more intensive upfront combination regimens, the frequency of these toxicities is rapidly growing with a potential negative effect also on patient's outcome, as a result of dose reductions, delays or even discontinuation of active treatments. Thus, identifying patients at higher risk of developing GIT as well as an optimal management are paramount in order to improve patient's compliance and outcome. After the description of the main treatment-induced GIT, we discuss the current knowledge on the pathophysiology of these side effects and comment the scales commonly used to assess and grade them. We then provide a critical update on GIT incidence based on the results of key randomized trials conducted in patients with metastatic colorectal cancer and advanced pancreatic cancer. | Giuseppe Aprile Karim Rihawi Elisa De Carlo Stephen T Sonis | 2015 | World Journal of Gastroenterology2015，21，41： | 7 |
| 3 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial显示文摘 | Yung-Jue Bang Eric Van Cutsem Andrea Feyereislova Hyun C Chung Lin Shen Akira Sawaki Florian Lordick Atsushi Ohtsu Yasushi Omuro Taroh Satoh Giuseppe Aprile Evgeny Kulikov Julie Hill Michaela Lehle Josef Rüschoff Yoon-Koo Kang | 2010 | The Lancet . 2010 (9742)2010，，9742： | 6 |
| 4 | Molecular classifications of gastric cancers: Novel insights and possible future applications显示文摘Despite some notable advances in the systemic management of gastric cancer(GC), the prognosis of patients with advanced disease remains overall poor and their chance of cure is anecdotic. In a molecularly selected population, a median overall survival of 13.8 mo has been reached with the use of human epidermal growth factor 2(HER2) inhibitors in combination with chemotherapy, which has soon after become the standard of care for patients with HER2-overexpressing GC. Moreover, oncologists have recognized the clinical utility of conceiving cancers as a collection of different molecularlydriven entities rather than a single disease. Several molecular drivers have been identified as having crucial roles in other tumors and new molecular classifications have been recently proposed for gastric cancer as well. Not only these classifications allow the identification of different tumor subtypes with unique features, but also they serve as springboard for the development of different therapeutic strategies. Hopefully, the application of standard systemic chemotherapy, specifictargeted agents, immunotherapy or even surgery in specific cancer subgroups will help maximizing treatment outcomes and will avoid treating patients with minimal chance to respond, therefore diluting the average benefit. In this review, we aim at elucidating the aspects of GC molecular subtypes, and the possible future applications of such molecular analyses. | Silvio Ken Garattini Debora Basile Monica Cattaneo Valentina Fanotto Elena Ongaro Marta Bonotto Francesca V Negri Rosa Berenato Paola Ermacora Giovanni Gerardo Cardellino Mariella Giovannoni Nicoletta Pella Mario Scartozzi Lorenzo Antonuzzo Nicola Silvestris Gianpiero Fasola Giuseppe Aprile | 2017 | World Journal of Gastrointestinal Oncology2017，9，5： | 5 |
| 5 | Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial显示文摘 | Charles S Fuchs Jiri Tomasek Cho Jae Yong Filip Dumitru Rodolfo Passalacqua Chanchal Goswami Howard Safran Lucas Vieira dos Santos Giuseppe Aprile David R Ferry Bohuslav Melichar Mustapha Tehfe Eldar Topuzov John Raymond Zalcberg Ian Chau William Campbell | 2014 | The Lancet2014，，9911： | 3 |
| 6 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial显示文摘 | Yung-Jue Bang Eric Van Cutsem Andrea Feyereislova Hyun C Chung Lin Shen Akira Sawaki Florian Lordick Atsushi Ohtsu Yasushi Omuro Taroh Satoh Giuseppe Aprile Evgeny Kulikov Julie Hill Michaela Lehle Josef Rüschoff Yoon-Koo Kang | 2010 | The Lancet2010，，9742： | 2 |
| 7 | Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial显示文摘 | Charles S Fuchs Jiri Tomasek Cho Jae Yong Filip Dumitru Rodolfo Passalacqua Chanchal Goswami Howard Safran Lucas Vieira dos Santos Giuseppe Aprile David R Ferry Bohuslav Melichar Mustapha Tehfe Eldar Topuzov John Raymond Zalcberg Ian Chau William Campbell | 2014 | 2014 (9911)2014，，9911： | 2 |
| 8 | Colonoscopic evaluation of hematochezia in low and average risk patients for colorectal cancer:A prospective study显示文摘AIM: To relate the endoscopic findings in patients with hematochezia with regard to age in “low and average risk” for colorectal cancer (CRC) and to localize signifi cant lesions in order to identify patients who need sigmoidoscopy or total colonoscopy. METHODS: This prospective study was performed in an open access GI endoscopy unit. Out of 4322 consecutive patients undergoing colonoscopy, 918 reported hema- tochezia. The fi nal study group comprized 180 patients aged below 45 and 237 over 45. Main exclusion criteria were a 1st-degree family history of colorectal carcinoma, patients reporting blood mixed with stools and/or pro- gressive colonic symptoms, or patients who had under- gone colon surgery for neoplastic lesions. RESULTS: Total colonoscopy could be performed in 96% of patients. Abnormal findings were observed in 34.3% of the younger and in 65.7% of the older ones. Findings were the presence of polyps in the distal colon (n = 2) and IBD in the proximal colon (n = 29) in the group of the younger patients, and polyps (n = 15), IBD (n = 13), and carcinoma (n = 6, 4 of the lesions were located proximal to the splenic flexure) in the elderly. Our f indings suggest that the diagnostic potential of total colonoscopy in patients younger than 45 referring scant hematochezia, is not mandatory. By exploring only the distal tract of the colon we have misdiagnosed two cases of IBD located in the ascending colon. In this group of patients additional risk factors must be identifi ed before performing a total colonoscopy. Regarding the patients older than 45 yr, the exploration of the distal colon would have led to our overlooking a carcinoma, two neoplastic polyps and one IBD located in the proximal colon. CONCLUSION: Young patients with scant hematochezia but without risk factors for neoplasia do not need a totalcolonoscopy, whereas is mandatory performing a total colonoscopy in older patients even in the presence of anal pathology. | Puglisi Carlo Russo Francesco Paolo Barbera Carmelo Incarbone Salvatore Aprile Giuseppe Bonanno Giacomo Russo Antonio | 2006 | World Journal of Gastroenterology2006，12，45： | 2 |
| 9 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial显示文摘 | Yung-Jue Bang Eric Van Cutsem Andrea Feyereislova Hyun C Chung Lin Shen Akira Sawaki Florian Lordick Atsushi Ohtsu Yasushi Omuro Taroh Satoh Giuseppe Aprile Evgeny Kulikov Julie Hill Michaela Lehle Josef Rüschoff Yoon-Koo Kang | 2010 | 2010 (9742)2010，，9742： | 2 |
| 10 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial显示文摘 | Yung-Jue Bang Eric Van Cutsem Andrea Feyereislova Hyun C Chung Lin Shen Akira Sawaki Florian Lordick Atsushi Ohtsu Yasushi Omuro Taroh Satoh Giuseppe Aprile Evgeny Kulikov Julie Hill Michaela Lehle Josef Rüschoff Yoon-Koo Kang | 2010 | The Lancet2010，，9742： | 1 |
| 11 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial显示文摘 | Yung-Jue Bang Eric Van Cutsem Andrea Feyereislova Hyun C Chung Lin Shen Akira Sawaki Florian Lordick Atsushi Ohtsu Yasushi Omuro Taroh Satoh Giuseppe Aprile Evgeny Kulikov Julie Hill Michaela Lehle Josef Rüschoff Yoon-Koo Kang | 2010 | The Lancet2010，，9742： | 1 |
| 12 | Rare cause of odynophagia: Giant esophageal ulcer显示文摘Gastrointestinal complications are a frequent cause of morbidity after transplantation and may affect up to 40% of kidney transplant recipients. Here we report a rare case of idiopathic giant esophageal ulcer in a kidney transplant recipient. A 37-year-old female presented with a one-week history of odynophagia and weight loss. Upon admission, the patient presented cold sores, and a quantitative cytomegalovirus polymerase chain reaction was positive(105 copies/ml). An upper endoscopy demonstrated the presence of a giant ulcer. Serological test and tissue biopsies were unable to demonstrate an infectious origin of the ulcer. Immunosuppression was reduced and everolimus was introduced. An empirical i.v. therapy with acyclovir was started, resulting in a dramatic improvement in symptoms and complete healing of the ulcer. Only two cases of idiopathic giant esophageal ulcer in kidney transplant recipients have been reported in the literature; in both cases, steroid therapy was successful without recurrence of symptoms or endoscopic findings. However, this report suggests that correction of immune imbalance is mandatory to treat such a rare complication. | Massimiliano Veroux Giuseppe Aprile Francesca F Amore Daniela Corona Alessia Giaquinta Pierfrancesco Veroux | 2016 | World Journal of Gastroenterology2016，22，14： | 1 |
| 13 | Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy显示文摘 | Dorothy M. Keefe Linda S. Elting Hoang T. Nguyen Steven M. Grunberg Giuseppe Aprile Antony Bonaventura Sudarsha Selva-Nayagam Andrea Barsevick Bogda Koczwara Stephen T. Sonis | 2014 | Cancer Chemotherapy and Pharmacology2014，，4： | 1 |
| 14 | Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial显示文摘 | Charles S Fuchs Jiri Tomasek Cho Jae Yong Filip Dumitru Rodolfo Passalacqua Chanchal Goswami Howard Safran Lucas Vieira dos Santos Giuseppe Aprile David R Ferry Bohuslav Melichar Mustapha Tehfe Eldar Topuzov John Raymond Zalcberg Ian Chau William Campbell | 2014 | The Lancet . 2014 (9911)2014，，9911： | 1 |
| 15 | Risk of unplanned visits for colorectal cancer outpatients receiving chemotherapy: a case-crossover study显示文摘 | Luisa Foltran Giuseppe Aprile Federica Edith Pisa Paola Ermacora Nicoletta Pella Emiliana Iaiza Elena Poletto Stefania Eufemia Lutrino Micol Mazzer Mariella Giovannoni Giovanni Gerardo Cardellino Fabio Puglisi Gianpiero Fasola | 2014 | Supportive Care in Cancer2014，，9： | 1 |
| 16 | Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial显示文摘 | Michele Reni Stefano Cereda Michele Milella Anna Novarino Alessandro Passardi Andrea Mambrini Giuseppe Di Lucca Giuseppe Aprile Carmen Belli Danova Marco Francesca Bergamo Enrico Franceschi Clara Fugazza Domenica Ceraulo Eugenio Villa | 2013 | European Journal of Cancer2013，，： | 1 |
| 17 | Oxaliplapin and Capecitabine (XELOX) Based Chemotherapy in the Treatment of Metastatic Colorectal Cancer: The Right Choice in Elderly Patients显示文摘 | Massimiliano Berretta Giuseppe Aprile Guglielmo Nasti Martina Urbani Alessandra Bearz Stefania Lutrino Luisa Foltran Laura Ferrari Renato Talamini Francesco Fiorica Arben Lleshi Vincenzo Canzonieri Chiara Lestuzzi Eugenio Borsatti Rossella Fisichella Umbe | 2013 | Anti-Cancer Agents in Medicinal Chemistry2013，，9： | 1 |
| 18 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial显示文摘 | Yung-Jue Bang Eric Van Cutsem Andrea Feyereislova Hyun C Chung Lin Shen Akira Sawaki Florian Lordick Atsushi Ohtsu Yasushi Omuro Taroh Satoh Giuseppe Aprile Evgeny Kulikov Julie Hill Michaela Lehle Josef Rüschoff Yoon-Koo Kang | 2010 | The Lancet2010，，9742： | 1 |
| 19 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial显示文摘 | Yung-Jue Bang Eric Van Cutsem Andrea Feyereislova Hyun C Chung Lin Shen Akira Sawaki Florian Lordick Atsushi Ohtsu Yasushi Omuro Taroh Satoh Giuseppe Aprile Evgeny Kulikov Julie Hill Michaela Lehle Josef Rüschoff Yoon-Koo Kang | 2010 | The Lancet2010，，9742： | 1 |
| 20 | Critical Appraisal of Ramucirumab (IMC-1121B) for Cancer Treatment: From Benchside to Clinical Use显示文摘 | Giuseppe Aprile Marta Bonotto Elena Ongaro Carmelo Pozzo Francesco Giuliani | 2013 | Drugs2013，，18： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员